AstraZeneca (AZN) Tops Q1 EPS by 20c

AstraZeneca (NASDAQ: AZN) reported Q1 EPS of $1.92, $0.20 better than the analyst estimate of $1.72. Revenue for the quarter came in at $10.88 billion versus the consensus estimate of $10.69 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM
• MP Materials seen largely insulated after China export-control move